Dr. Linda Stein Gold MD Director of Dermatology Clinical Research at Henry Ford Health System Detroit, Michigan Division Head of Dermatology Henry Ford Health System in West Bloomfield, Michigan

DUOBRII® : Halobetasol and Tazarotene Combination Lotion May Provide Durable Psoriasis Remission

MedicalResearch.com Interview with:

Dr. Linda Stein Gold MD Director of Dermatology Clinical Research at Henry Ford Health System Detroit, Michigan Division Head of Dermatology Henry Ford Health System in West Bloomfield, Michigan

Dr. Stein Gold

Dr. Linda Stein Gold MD
Director of Dermatology Clinical Research at Henry Ford Health System
Detroit, Michigan
Division Head of Dermatology
Henry Ford Health System in West Bloomfield, Michigan

MedicalResearch.com: What is the background for this study?

Response: Halobetasol and Tazarotene work by complimentary mechanisms of action in treating psoriasis and also have been shown to counteract the side effects associated with the other medications.

In prior studies using tazarotene as monotherapy, there was a maintenance of effect even after the drug was discontinued. We investigated to see if there was a maintenance of treatment effect in patients who achieved clear skin after using the fixed combination of halobetasol propionate 0.01%/tazarotene 0.045% lotion for 8 weeks of daily treatment. 

I served as lead author on the study, which was presented Fall Clinical Dermatology Conference this weekend in a poster titled, “Long-term management of moderate-to-severe plaque psoriasis: maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion.”

MedicalResearch.com: What should readers take away from your report? 

Response: In this 1-year, open-label study of Halobetasol Propionate/Tazarotene, 53.6% of participants who achieved clear skin (IGA score of 0) did not require retreatment for more than 12 weeks. 

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: It may be possible to provide patients with a durable remission of their psoriasis after treatment with this fixed combination.

Any disclosures?

I am an investigator, advisor and speaker for Ortho Dermatologics.

Citation:

Long-term management of moderate-to-severe plaque psoriasis: maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion

[subscribe]

Last Modified: [last-modified]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Last Updated on October 29, 2020 by Marie Benz MD FAAD